EFFICACY OF TIRZEPATIDE IN THE CLINICAL MANAGEMENT OF OBESITY IN ADULTS: A LITERATURE REVIEW

Abstract

Obesity is a chronic and complex condition that requires multifaceted therapeutic approaches. Thus, tirzepatide, a dual-action medication combining GIP and GLP-1 receptor agonist effects, has demonstrated significant benefits in weight reduction and improvement of metabolic parameters in obese patients. This study aims to analyze the efficacy of tirzepatide therapy in the control of obesity. An Integrative Literature Review was conducted, with searches in PUBMED and BVS using the English Health Sciences Descriptors "Obesity," "Tirzepatide," "efficacy," and "Adults," combined with the boolean operator AND. The results highlighted that the GIP and GLP-1 analog is superior to other incretinomimetics, achieving a weight reduction rate greater than 5%, with improvements in cardiometabolic health, reducing pre-existing cardiovascular and atherosclerotic risks. However, it has some contraindications, including its use in pregnant women, patients with endocrine-metabolic neoplasms, or a family history of these conditions, as well as gastrointestinal adverse reactions, risk of pancreatitis, liver diseases, and risk of withdrawal. It is concluded that despite its effects, the therapy is beneficial for implementation in the treatment of obesity.